Abstract: Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group.

Abstract: The present invention is directed to methods of preventing and/or treating infectious disease. In a particular aspect, the invention is directed to treating viral infections by administering an isolated Prothymosin alpha molecule (SEQ ID NO: 2) to a subject in a therapeutically effective amount that reduces the symptoms associated with the viral infection. In a more particular embodiment, the viral infection is caused by a retrovirus, a lentivirus, or a hepatitis virus. In a particular aspect, the viral infection is caused by human immunodeficiency virus-1.

Abstract: The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin ?5? 1. Most of the FGF-2-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Using function-blocking antibodies and peptides, a specific contribution of ?5?1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated.

Abstract: Fused heterocyclic compounds are disclosed that have formula 1: where A, B, L, N, R1, R3, R4?, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

Abstract: The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon cancers, as well as in methods of treatment of such cancers.

Abstract: The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis using agents that inhibit the sonic hedgehog and GLI signaling pathway, including agents that inhibit GLI expression, synthesis and/or function. The present invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of cancer. Methods of treating cancer, including glioblastomas, medulloblastomas, basal cell carcinomas, prostate cancer and small cell and non-small cell lung cancer are also provided using small organic compounds, siRNAs and blocking antibodies that inhibit or block the SHH/GLI pathway.

Abstract: A method is disclosed for providing a correcting factor for the dilution of measurements of at least one biomarker in cerebrospinal fluid (CSF). The method comprises providing semi-automated measurements of the ventricular system by MRI scans using quantitative anatomical protocols, determining a measurement of biomarker levels in CSF that has been extracted, correcting the measurement of the level of said at least one biomarker according to the ventricular size, and providing a corrected result of the measurement determined in step (b), said corrected result accounting for concentration dilution due to the change in ventricular size. The method is particularly suited for the measurement of all biomarkers found in the CSF, such as those associated with mild cognitive impairment (MCI) and Alzheimer's Disease.

Abstract: The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated development of a T cell lymphoproliferative disorder or B cell plasma cell tumor, together with the identification of cells transduced with the ALK tyrosine kinase gene or fusion proteins thereof, and methods for using this animal model and cells for screening compounds or treatments for antitumor activity. In preferred embodiments, the animal is a transgenic mouse that expresses a human NPM-ALK gene operably linked to human regulatory sequences, and the cells of the mouse have at least one copy of the NPM-ALK transgene, whereby the mouse constitutively expresses a protein encoded by the NPM-ALK transgene. The animals and cells of the invention are useful in the study of NPM-ALK-dependent lymphomagenesis and plasma cell tumors and in the development of treatments for these conditions.

Abstract: The device and method disclosed deals with the operation of a cross-band simplex radio frequency communications system. In a system having a first band receiver on a first radio frequency band for receiving and demodulating a first received signal, and a second band transmitter using a second radio frequency band to modulate and transmit the demodulated first received signal so as to communicate audio and signaling received by the receiver in one band to the transmitter of another band when in a cross band mode. There is also at least a second band receiver using the second radio frequency band typically associated with the second frequency band transmitter for receiving signals containing audio and signaling which is to be communicated to a first band transmitter so as to reply to the signal received on the first band receiver.

Abstract: The invention relates to a simplified digital wiring system for vehicles. The invention comprises a synchronisation generator (2) which is connected to a plurality of multiplexer modules (1a, 1b, 1b?) via a synchronisation (6) and, at other times, data line. In turn, the aforementioned multiplexer modules (1a, 1b, 1b?) are connected to a plurality of inputs and/or outputs for receiving/transmitting data from/to electroelectronic devices, such that the synchronisation generator selects a multiplexer module so that said module manages the inputs and/or outputs thereof and, in this way, can control the operations of the different electroelectronic devices (13-19). Moreover, the multiplexer modules can be connected to the synchronisation generator (2) in parallel (1a) or in series (1b, 1b?). The invention is advantageous in that the multiplexer modules (1a, 1b, 1b?) are connected using a single synchronisation (6) and data (7) line, thereby simplifying the wiring.

Abstract: Advertising apparatus for vending machines, mainly of the type of those which have a glass front which allows the products to be seen presented in the different compartments of the plurality of storage trays and from which compartments they are delivered to a reception tray formed in an ascending/descending body, by way of an elevator, for their carriage to the delivery box for collection by the user, so that to the ascending/descending body (7), proximate to the internal face of the glass door (2) of the machine (1), is fastened, by one of its sides, a laminar element (9) that holds publicity, which laminar element (9) on its opposing side is fastened to and wound on a winding roller (10), which is driven by a spring tending to cause its rotation and the winding of the laminar element (9), the laminar element (9) in the unwinding thereof remaining abutting on the internal face of the glass front (3) of the machine door.

Abstract: The present invention relates to the use of post source decay (PSD) or collision induced dissociation (CID) direct tissue (DT) MALDI-TOF or DT-MALDI-TOF-TOF mass spectrographic identification of biological molecules in a tissue or cellular sample without the need for further protein extraction. This method provides for studying cells or tissues by direct tissue MALDI (DT-MALDI), thereby substituting in situ protein release for further protein extraction. Mass/intensity data was processed with Mascot© software interrogation of the NCBI database. These results are proof of principle that DT-MALDI, combined with bioinformatics, can directly identify proteins in cells and tissues from their mass spectra.

Abstract: The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and Gli signaling pathway, including agents that inhibit GLI synthesis and/or function. The present invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of melanomas. Methods of treating cancer, including melanoma are also provided using small organic compounds, siRNAs and blocking antibodies that inhibit or block the SHH/GLI pathway. In addition, the use of agents that inhibit other signaling pathways is contemplated for use as second agents to be used in conjunction with the inhibitors of the GLI pathway.

Abstract: The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Abeta protein, including abeta1-42 are prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode/disorder attributed to elevated levels of Abeta protein, including abeta1-42, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders by administering an agent that either prevents production of Abeta, prevents aggregation of Abeta fibrils, or that increases the degradation or clearance of Abeta. In addition, the invention provides a method of treating or preventing a major or minor depressive disorder comprising administering an agent that prevents or interferes with Abeta-induced neurotoxicity.

Abstract: A vehicle stabilization device for use in stabilizing a vehicle to enable safe and rapid victim extrication operations by first responder and other personnel. The device includes a base plate for enabling its emplacement on an underlying support surface beneath the vehicle to be stabilized. First and second extender members, each having a base end and a distal end, are hingedly connected to each other at their distal ends. The base ends are rotably mounted to the base plate and are moveable toward each other from an initial spaced position. This reduction of spacing between the base ends acts in conjunction with the hinged attachment between the distal ends to increasingly incline the extender members with respect to the base plate and thereby increasingly elevate the distal ends above the base plate. A vehicle contact and support member is secured to the distal hinged ends, and elevates with the distal ends of the extender members until contact is made with the overlying portion of the vehicle.

Abstract: A vascular access needle assembly is provided. The needle assembly includes a housing interconnected with a needle. The housing and the needle have slots along their lengths which are aligned to form a slot extending along the entire needle assembly. A sheath interconnected with the needle extends partially about the needle and includes a slot. The vascular access needle, with the needle point exposed and needle slot closed, can be inserted into the blood vessel of a subject and a guide wire can be inserted into the blood vessel through the needle assembly. The sheath is then moved to cover the needle point and to expose the needle slot so that the guide wire can be lifted through the needle, sheath and housing slots and the vascular access needle assembly removed, leaving the guide wire in the subject. The device can also be used as a wire introducer for catheters.

Abstract: A safety syringe and cap holding device for holding a syringe which also allows the syringe to be capped and uncapped while minimizing exposure of the user's hands to the hazard of needle sticks. The cap holding device can be powered electrically or mechanically, and can be selectively operated by a user.